Lacidipin Belupo

Lacidipine, the active ingredient in Lacidipin Belupo, is a dihydropyridine calcium channel blocker presented as a tablet for oral use. It lowers blood pressure in adults with hypertension.

GNH USA supplies Lacidipin Belupo as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacidipine is used to treat hypertension, a condition characterized by elevated arterial pressure.

- Hypertension: reduces systolic and diastolic blood pressure in adult patients. - Essential hypertension: improves overall blood pressure control. - Isolated systolic hypertension: helps lower high systolic readings.

Lacidipine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: warm sensation, especially on the face. - Dizziness or light‑headedness. - Peripheral edema: swelling of ankles or feet. - Nausea or abdominal discomfort. - Tachycardia: increased heart rate.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure. - Myocardial infarction: rare but possible cardiac event. - Hepatic dysfunction: abnormal liver enzymes. - Allergic reactions: rash, pruritus, or urticaria. - Angioedema: swelling of lips, tongue, or throat. - Syncope: fainting episodes.

Before initiating Lacidipine therapy, several safety considerations should be observed.

- Monitor blood pressure: ensure adequate control and avoid excessive drops. - Assess for peripheral edema: watch for swelling, especially in patients with heart failure. - Avoid abrupt discontinuation: taper dose to prevent rebound hypertension. - Caution in hepatic impairment: dose adjustment may be required. - Avoid concomitant strong CYP3A4 inhibitors: may increase Lacidipine levels. - Store at room temperature: keep in the original pack, protect from moisture.

Lacidipine can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Other calcium channel blockers: additive hypotensive effect. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase plasma concentration. - Grapefruit juice: may elevate drug levels.

Moderate Interactions (Monitor Closely):\n- Beta‑blockers: enhanced blood pressure lowering. - Diuretics: risk of excessive hypotension. - ACE inhibitors or ARBs: potential for additive renal effects.